Alle verbonden artikelen

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Auteurs : Cardoso F, Vant Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, Delorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart-Gebhart M
Jaar : 2016
Journal : N Engl J Med
Volume : 375(8)
Pagina's : 717-29

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Auteurs : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Jaar : 2016
Journal : Eur J Cancer
Volume : 60
Pagina's : 117-124

Immune checkpoint inhibitors renal side effects and management.

Auteurs : Rassy EE, Kourie HR, Rizkallah J, Karak FE, Hanna C, Chelala DN, Ghosn M
Jaar : 2016
Journal : Immunotherapy
Volume : 8
Pagina's : 1417-1425

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.

Auteurs : Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, Dhont L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N
Jaar : 2016
Journal : Urol Oncol
Volume : 34(6)
Pagina's : 254.e7-254.e13

The Future of Access to Innovative Medicines in Cancer Therapy: Towards Conditional Dialogue Fostering Affordable Therapeutic Innovation

Auteurs : van Dyk N, De Greve J, Schots R, Awada A, Van Eycken L, Geldof T
Jaar : 2016
Journal : Vlerick business school
Volume : 7
Pagina's : -

Immune checkpoint inhibitors side effects and management.

Auteurs : Kourie HR, Klastersky J
Jaar : 2016
Journal : Immunotherapy
Volume : 8
Pagina's : 799-807

Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.

Auteurs : Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, Dhoore A, Iserentant H, Hendlisz A, Mazzone M
Jaar : 2016
Journal : Gut
Volume : 65(6)
Pagina's : 990-1000

Too little benefit for too much toxicity: rethinking the adjuvant development model in colon cancer.

Auteurs : Hendlisz A, Bleiberg H
Jaar : 2016
Journal : Curr Opin Oncol
Volume : 28(4)
Pagina's : 345-7

Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.

Auteurs : Habre M, Habre SB, Kourie HR
Jaar : 2016
Journal : Immunotherapy
Volume : 8
Pagina's : 1437-1446

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Auteurs : Strasser-Weippl K, Horick N, Smith IE, O Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE
Jaar : 2016
Journal : Eur J Cancer
Volume : 56
Pagina's : 85-92

Progressive multifocal leukoencephalopathy mimicking cerebral metastases in a patient treated for nasopharyngeal carcinoma

Auteurs : Oualla K, Aoun F, Lemort M, Harrouk A, Latifyan S, Awada A, Georgala A
Jaar : 2016
Journal : Belgian J Medical Oncology
Volume : 10(7)
Pagina's : 276-280

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Auteurs : Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart-Gebhart M, Dowsett M, Michiels S, Leyland-Jones B
Jaar : 2016
Journal : JAMA Oncol
Volume : 2(8)
Pagina's : 1040-7

Supportive/palliative care in cancer patients: quo vadis?

Auteurs : Klastersky J, Libert I, Michel B, Obiols M, Lossignol D
Jaar : 2016
Journal : Support Care Cancer
Volume : 24(4)
Pagina's : 1883-8

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Auteurs : Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M
Jaar : 2016
Journal : Lancet Oncol
Volume : 17(3)
Pagina's : 357-66

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.

Auteurs : Twelves C, Jove M, Gombos A, Awada A
Jaar : 2016
Journal : Crit Rev Oncol Hematol
Volume : 100
Pagina's : 74-87

Understanding the risk for infection in patients with neutropenia.

Auteurs : Klastersky J, Meert AP
Jaar : 2016
Journal : Intensive Care Med
Volume : 42(2)
Pagina's : 268-70

Do the Guidelines in Oncology Need to Evolve?

Auteurs : Awada A, Awada G, Hendlisz A
Jaar : 2016
Journal : Eur Med J
Volume : -
Pagina's : 15

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. (Springerplus)

Auteurs : Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, OShaughnessy J
Jaar : 2016
Journal : Springerplus
Volume : 5
Pagina's : 1033

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Auteurs : Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M
Jaar : 2016
Journal : ESMO Open
Volume : 1
Pagina's : e000107

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.

Auteurs : Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van den Bulck H, Smeets A, Bechter O, Kini Bailur J, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem G, Wildiers H
Jaar : 2016
Journal : Oncotarget
Volume : 7(21)
Pagina's : 29977-88